AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29149349 — intervention group
Group type: EXPERIMENTAL
Intervention: Social exclusion (manipulated using the Cyberball game)
Number of subjects: 74
Study 27676420 — intervention group
Group type: COMPARATOR
Intervention: Standard behavioral weight intervention (single weight counseling session)
Number of subjects: 203
Study 27676420 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense behavioral weight intervention (weight counseling at each study visit)
Number of subjects: 203
Study 27676420 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5-20 mg/day)
Number of subjects: 203
Study 25038733 — intervention group
Group type: EXPERIMENTAL
Intervention: DCEAS plus SSRI plus body electroacupuncture (n = 23)
Number of subjects: 43
Study 25038733 — intervention group
Group type: COMPARATOR
Intervention: Sham (non-invasive cranial electroacupuncture, n-CEA) plus SSRI plus body electroacupuncture (n = 20)
Number of subjects: 43
Study 21918812 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 21
Study 21918812 — intervention group
Group type: COMPARATOR
Intervention: Prudent diet
Number of subjects: 21
Study 20688314 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost plus timolol
Number of subjects: 89
Study 20688314 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost plus timolol
Number of subjects: 89
Study 18277180 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise training (TRAINED; n=8)
Number of subjects: 14
Study 18277180 — intervention group
Group type: COMPARATOR
Intervention: Attention-time control (CONTROL; n=6)
Number of subjects: 14
Study 15877227 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-FDG PET
Number of subjects: 28
Study 15877227 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc-depreotide SPECT
Number of subjects: 28
Study 15877227 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 28
Study 14516219 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-based prospective memory with varying intention complexity
Number of subjects: 0
Study 14516219 — intervention group
Group type: COMPARATOR
Intervention: Ongoing task performance
Number of subjects: 0
Study 10880787 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral stimulus and response conditions
Number of subjects: 15
Study 10880787 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual P1 microstates
Number of subjects: 15
Study 10880787 — intervention group
Group type: EXPERIMENTAL
Intervention: Central P3 and pre-/post-response microstates
Number of subjects: 15
Study 10880787 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateralized readiness potential
Number of subjects: 15
Study 10880787 — intervention group
Group type: COMPARATOR
Intervention: Control group (16 boys)
Number of subjects: 15
Study 8650966 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based medicine approaches in medical education
Number of subjects: 0
Study 8650966 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochrane Collaboration methodologies
Number of subjects: 0
Study 8650966 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled studies
Number of subjects: 0
Study 1348916 — intervention group
Group type: EXPERIMENTAL
Intervention: nebivolol 5 mg once a day
Number of subjects: 23
Study 2946740 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine, 10 mg four times daily for 6 months
Number of subjects: 241
Study 2946740 — intervention group
Group type: COMPARATOR
Intervention: Placebo four times daily for 6 months
Number of subjects: 241
Study 2946740 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (compliant patients)
Number of subjects: 241
Study 2946740 — intervention group
Group type: COMPARATOR
Intervention: Placebo (compliant patients)
Number of subjects: 241
Study 30355395 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked eggplant and cooked rice (CE+R)
Number of subjects: 16
Study 30355395 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked pak choi and cooked rice (CP+R)
Number of subjects: 16
Study 30355395 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked cauliflower and cooked rice (CC+R)
Number of subjects: 16
Study 30355395 — intervention group
Group type: COMPARATOR
Intervention: Homogenised counterparts of CE+R, CP+R, and CC+R
Number of subjects: 16
Study 30355395 — intervention group
Group type: COMPARATOR
Intervention: Pure rice
Number of subjects: 16
Study 27207511 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin treatment
Number of subjects: 9
Study 23398229 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief interventions (BIs) for risk-drinking women
Number of subjects: 20
Study 21552672 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise session
Number of subjects: 10
Study 21552672 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise session
Number of subjects: 10
Study 21552672 — intervention group
Group type: COMPARATOR
Intervention: Control session (no exercise)
Number of subjects: 10
Study 19461297 — intervention group
Group type: EXPERIMENTAL
Intervention: AWS with bougie
Number of subjects: 30
Study 19461297 — intervention group
Group type: COMPARATOR
Intervention: AWS only
Number of subjects: 30
Study 17704494 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA) with selective stent placement
Number of subjects: 279
Study 17704494 — intervention group
Group type: COMPARATOR
Intervention: Primary stent placement
Number of subjects: 279
Study 14760126 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine at 100 mg/m2 or 50 mg/m2 concurrent with radiotherapy (70 Gy over 7 weeks)
Number of subjects: 27
Study 11704374 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled carbon monoxide (CO) at 1,200 ppm to 1,500 ppm
Number of subjects: 12
Study 11704374 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (20 cigarettes per day)
Number of subjects: 12
Study 11704374 — intervention group
Group type: COMPARATOR
Intervention: Inhaled air
Number of subjects: 12
Study 9566060 — intervention group
Group type: EXPERIMENTAL
Intervention: Iridium-192
Number of subjects: 55
Study 9566060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 8065190 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine type 2 receptor antagonists
Number of subjects: 0
Study 8065190 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole therapy
Number of subjects: 0
Study 8065190 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotility agents and surgical therapy
Number of subjects: 0
Study 2903811 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 2
Study 2903811 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 2
Study 2903811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 31356702 — intervention group
Group type: EXPERIMENTAL
Intervention: BCT+IBT
Number of subjects: 61
Study 31356702 — intervention group
Group type: COMPARATOR
Intervention: IBT
Number of subjects: 61
Study 28574026 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise (heart rate reserve 40-60%) for 8 weeks
Number of subjects: 87
Study 28574026 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 87
Study 26142341 — intervention group
Group type: EXPERIMENTAL
Intervention: Danlou Tablet (4.5 g/day for 2 days before intervention, with a further 4.5 g/day for 90 days thereafter)
Number of subjects: 220
Study 26142341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 26142341 — intervention group
Group type: EXPERIMENTAL
Intervention: Danlou Tablet
Number of subjects: 220
Study 23336123 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled Telephone Intervention (STI)
Number of subjects: 49
Study 23336123 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 49
Study 22105265 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoxynol-9 vaginal gel
Number of subjects: 30
Study 22105265 — intervention group
Group type: COMPARATOR
Intervention: Control (hydroxyethyl cellulose placebo)
Number of subjects: 30
Study 19965295 — intervention group
Group type: EXPERIMENTAL
Intervention: CT colonography (CTC)
Number of subjects: 0
Study 19965295 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert panel recommendations
Number of subjects: 0
Study 19965295 — intervention group
Group type: COMPARATOR
Intervention: Centers for Medicare and Medicaid Services (CMS) decision
Number of subjects: 0
Study 22852059 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular consumption of fresh lean pork (up to 1 kg/week)
Number of subjects: 164
Study 22852059 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintain habitual diet)
Number of subjects: 164
Study 16005801 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamfer preparation
Number of subjects: 90
Study 16005801 — intervention group
Group type: EXPERIMENTAL
Intervention: 135 degrees shoulder preparation
Number of subjects: 90
Study 16005801 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 degrees shoulder preparation
Number of subjects: 90
Study 16005801 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingival level preparations
Number of subjects: 90
Study 16005801 — intervention group
Group type: COMPARATOR
Intervention: PVS impressions
Number of subjects: 90
Study 16005801 — intervention group
Group type: COMPARATOR
Intervention: C-silicone impressions
Number of subjects: 90
Study 16005801 — intervention group
Group type: COMPARATOR
Intervention: One-stage putty-wash technique
Number of subjects: 90
Study 16005801 — intervention group
Group type: COMPARATOR
Intervention: Two-stage putty-wash technique
Number of subjects: 90
Study 12211684 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal ultrasound screening of all hips
Number of subjects: 15529
Study 12211684 — intervention group
Group type: COMPARATOR
Intervention: Selective ultrasound screening (only for those at risk)
Number of subjects: 15529
Study 9795412 — intervention group
Group type: EXPERIMENTAL
Intervention: Information form 1 (DIOmed)
Number of subjects: 218
Study 9795412 — intervention group
Group type: EXPERIMENTAL
Intervention: Information form 2 (perimed compliance)
Number of subjects: 218
Study 9795412 — intervention group
Group type: EXPERIMENTAL
Intervention: Information form 3 (PERIMED‐spitta)
Number of subjects: 218
Study 8585970 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrandrine
Number of subjects: 321
Study 8585970 — intervention group
Group type: COMPARATOR
Intervention: Calcium channel blockers (including nifedipine, verapamil, cinnarizine, tetrandrine)
Number of subjects: 321
Study 2571822 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis program (CAD‐A)
Number of subjects: 6962
Study 2571822 — intervention group
Group type: EXPERIMENTAL
Intervention: Amended program (DIAG)
Number of subjects: 6962
Study 2571822 — intervention group
Group type: COMPARATOR
Intervention: Clinical performance
Number of subjects: 6962
Study 204954 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenously administered oestrogens
Number of subjects: 0
Study 204954 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibrate
Number of subjects: 0
Study 204954 — intervention group
Group type: COMPARATOR
Intervention: Depressed patients
Number of subjects: 0
Study 204954 — intervention group
Group type: COMPARATOR
Intervention: Perimenopausal female controls
Number of subjects: 0
Study 29435729 — intervention group
Group type: EXPERIMENTAL
Intervention: Kuanxiong Aerosol (KA)
Number of subjects: 750
Study 29435729 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (NT)
Number of subjects: 750
Study 26710670 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational interviewing (MI)
Number of subjects: 48
Study 26710670 — intervention group
Group type: EXPERIMENTAL
Intervention: MI plus normative feedback (NF)
Number of subjects: 48
Study 26710670 — intervention group
Group type: COMPARATOR
Intervention: Control group (MI only)
Number of subjects: 48
Study 24065190 — intervention group
Group type: EXPERIMENTAL
Intervention: Merocel(®) packs
Number of subjects: 50
Study 24065190 — intervention group
Group type: COMPARATOR
Intervention: Silicone splints
Number of subjects: 50
Study 24089691 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral naltrexone
Number of subjects: 54
Study 24089691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 22435613 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe whole leaf extract (AL with vitamins B(12), 1 mg and vitamin C 500 mg)
Number of subjects: 15
Study 22435613 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe fillet gel (AG with B(12) 1 mg and vitamin C 500 mg)
Number of subjects: 15
Study 22435613 — intervention group
Group type: COMPARATOR
Intervention: Water (with vitamin B(12) 1 mg and vitamin C 500 mg)
Number of subjects: 15
Study 19157139 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of traditional Chinese medicine (Changpikang) and ear acupoint therapy
Number of subjects: 262
Study 19157139 — intervention group
Group type: COMPARATOR
Intervention: Traditional Chinese medicine group (Changpikang)
Number of subjects: 262
Study 19157139 — intervention group
Group type: COMPARATOR
Intervention: Ear acupoint group (spleen, large intestine, sympathesis, subcortex)
Number of subjects: 262
Study 19157139 — intervention group
Group type: COMPARATOR
Intervention: Treatment group (sulfasalazine)
Number of subjects: 262
Study 19157139 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicine and acupoint group (Changpikang and ear acupoint)
Number of subjects: 262
Study 16176505 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (400 microg)
Number of subjects: 150
Study 16176505 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal misoprostol (400 microg)
Number of subjects: 150
Study 16176505 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two lactose tablets rectally)
Number of subjects: 150
Study 12925933 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (acetylcholinesterase inhibitor) for 12 weeks
Number of subjects: 6
Study 12925933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 10820860 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide foam (1 mg/50 ml b.i.d.)
Number of subjects: 33
Study 10820860 — intervention group
Group type: COMPARATOR
Intervention: Mesalazine enemas (4 g/60 ml o.d.)
Number of subjects: 33
Study 10820860 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 33
Study 8875971 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20-40 mg/day
Number of subjects: 0
Study 8875971 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg/day
Number of subjects: 0
Study 8875971 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fluvastatin plus niacin
Number of subjects: 0
Study 8875971 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin 20 or 40 mg/day
Number of subjects: 0
Study 1906028 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU of recombinant interferon alfa‐2b
Number of subjects: 90
Study 1906028 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 MU of recombinant interferon alfa‐2b
Number of subjects: 90
Study 1906028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 7039646 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 80 micrograms
Number of subjects: 68
Study 7039646 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (control)
Number of subjects: 68
Study 31336654 — intervention group
Group type: EXPERIMENTAL
Intervention: CIT- PROT- (Citrulline with low protein intake)
Number of subjects: 73
Study 31336654 — intervention group
Group type: EXPERIMENTAL
Intervention: CIT- PROT+ (Citrulline with high protein intake)
Number of subjects: 73
Study 31336654 — intervention group
Group type: COMPARATOR
Intervention: PLA-PROT- (Placebo with low protein intake)
Number of subjects: 73
Study 31336654 — intervention group
Group type: COMPARATOR
Intervention: PLA-PROT+ (Placebo with high protein intake)
Number of subjects: 73
Study 29290052 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg of hydrocortisone
Number of subjects: 49
Study 29290052 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline solution
Number of subjects: 49
Study 27129045 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP-2/ACS
Number of subjects: 0
Study 27129045 — intervention group
Group type: COMPARATOR
Intervention: Allograft
Number of subjects: 0
Study 25406552 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy plus oral flunarizine
Number of subjects: 90
Study 25406552 — intervention group
Group type: COMPARATOR
Intervention: Oral flunarizine alone
Number of subjects: 90
Study 23098345 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital aspirin
Number of subjects: 10
Study 23098345 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin in recommended initial dose (160-325 mg)
Number of subjects: 10
Study 23098345 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel during hospitalization
Number of subjects: 10
Study 23098345 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic coronary angiography
Number of subjects: 10
Study 23098345 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary interventions (PCI)
Number of subjects: 10
Study 23098345 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graftings
Number of subjects: 10
Study 23098345 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality in high risk patients (GRACE score >140)
Number of subjects: 10
Study 19751366 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 3
Study 18845288 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacrocolpopexy (SC)
Number of subjects: 322
Study 16093252 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy plus 270 mg mebeverine taken thrice daily
Number of subjects: 149
Study 16093252 — intervention group
Group type: COMPARATOR
Intervention: Mebeverine alone
Number of subjects: 149
Study 12625151 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrantel-oxantel (10 mg/kg)
Number of subjects: 1329
Study 12625151 — intervention group
Group type: COMPARATOR
Intervention: Mebendazole (500 mg)
Number of subjects: 1329
Study 12434648 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine 10 mg per os
Number of subjects: 10
Study 12434648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9884251 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral
Number of subjects: 390
Study 9884251 — intervention group
Group type: COMPARATOR
Intervention: Sandimmun
Number of subjects: 390
Study 7640495 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol extraction of Abelmoschus manihot, Gliclazide and Captopril tablets
Number of subjects: 68
Study 7640495 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide and Captopril tablets
Number of subjects: 68
Study 2719459 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg orally
Number of subjects: 201
Study 2719459 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin 3.0 g plus probenecid 1.0 g orally
Number of subjects: 201
Study 385458 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g cimetidine per day
Number of subjects: 60
Study 385458 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical tablets containing lactose)
Number of subjects: 60
Study 31389308 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower than optimum power load (LOPL; 20% lower than OPL)
Number of subjects: 23
Study 31389308 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher than optimum power load (HOPL; 20% higher than OPL)
Number of subjects: 23
Study 31150953 — intervention group
Group type: EXPERIMENTAL
Intervention: Paid Family Leave (PFL) policy
Number of subjects: 0
Study 31150953 — intervention group
Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 0
Study 29109658 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-needle arthrocentesis with distension of the upper compartment of the TMJ (1N)
Number of subjects: 26
Study 29109658 — intervention group
Group type: COMPARATOR
Intervention: Conventional two-needle arthrocentesis (2N)
Number of subjects: 26
Study 29109658 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques (1N and 2N)
Number of subjects: 26
Study 25609940 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium 50 μg once daily
Number of subjects: 460
Study 25609940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 460
Study 22453076 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting capillary blood glucose (FCG) measurement
Number of subjects: 993
Study 22453076 — intervention group
Group type: COMPARATOR
Intervention: Fasting venous plasma glucose (FPG) measurement
Number of subjects: 993
Study 21086010 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with low level laser therapy (LLLT)
Number of subjects: 36
Study 21086010 — intervention group
Group type: COMPARATOR
Intervention: Training only (TG)
Number of subjects: 36
Study 21086010 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 36
Study 21086010 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with LLLT (TLG)
Number of subjects: 36
Study 19494484 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 300 U/kg intravenously before surgery
Number of subjects: 71
Study 19494484 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo) intravenously before surgery
Number of subjects: 71
Study 19494484 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Number of subjects: 71
Study 18037816 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine skin patch
Number of subjects: 10
Study 18037816 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 10
Study 15514884 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile preparation of the root canal with maillefer thermafil filling (Group A)
Number of subjects: 0
Study 15514884 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile preparation of the root canal with iodoform cataplasm and gutta percha filling (Group B)
Number of subjects: 0
Study 15514884 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation of the root canal with stainless steel hand-operated instruments, iodoform cataplasm and gutta percha filling (Group C)
Number of subjects: 0